Skip to main content

Drug Side Effect Prediction and Validation


There's a paper just published in Nature getting a lot of coverage on the internet at the moment from Novartis/UCSF, and for good reason - but as the cartoon above states, it will probably have less impact than news on Justin Bieber's new haircut, or the latest handbags from Christian Lacroix. It uses the SEA target prediction method, trained using ChEMBL bioactivity data in order to predict new targets (and then by association side effects) for existing drugs. These are then experimentally tested, and the results confirmed in a number of cases - this experimental validation is clearly complex and expensive, so it is great news that in silico methods can start to generate realistic and testable hypotheses for adverse drug reactions (there are also positive side effects too, and these are pretty interesting to look for using these methods as well).

The use of SEA as the target prediction method was inevitable given the authors involved, but following up on some presentations at this springs National ACS meeting in San Diego. There would also seem to be clear benefits in including other methods into linking a compound to a target - nearest neighbour using simple Tanimoto measures, and naive Bayes/ECFPP type approaches. The advantage of the SEA approach is that it seems to generalise better (sorry I can't remember who gave the talk on this), and so probably can make more comprehensive/complete predictions, and be less tied to the training data (in this case ChEMBL) - however as databases grow, these predictions will get a lot better. There will also be big improvements possible if other data adopts the same basic data model as ChEMBL (or something like the services in OpenPHACTS), so methods can pool across different data sources, including proprietary in-house data.

There are probably papers being written right now about a tournament/consensus multi-method approach to target prediction using an ensemble of the above methods. (If such a paper uses random forests, and I get asked to review it, it will be carefully stored in /dev/null) ;)

So some things I think are useful improvements to this sort of approach.

1) Inclusion of the functional assays from ChEMBL in predictions (i.e. don't tie oneself to a simple molecular target assay). The big problem here though is that although pooling of target bioassay data is straightforward - pooling/clustering of functional data is not.
2) Where do you set affinity thresholds, and how do the affinities related to the pharmacodyamics of the side-effects. My view is that there will be some interesting analyses of ChEMBL that maybe, just maybe, allow one to address this issue. Remember, we know quite a lot about the exposure of the human body, to  a given drug at a given dose level...
3) Consideration of (active) metabolites. It's pretty straightforward now to predict structures of likely metabolites (not at a quantitative level though) and this may be useful in drugs that are extensively metabolised in vivo.

Anyway, finish off with some eye-candy, a picture from the paper (hopefully allowed under fair use!).


And here's a reference to the paper, in good old Bell AT&T labs refer format - Mendeley-Schmendeley as my mother used to say when I was a boy.

%T Large-scale prediction and testing of drug activity on side-effect targets
%A E. Lounkine
%A M.J. Keiser
%A S. Whitebread
%A D. Mikhailov
%A J. Hamon
%A J.L. Jenkins
%A P. Lavan
%A E. Weber
%A A.K. Doak
%A S. Côté
%A B.K. Shoichet
%A L. Urban
%J Nature
%D 2012
%O doi:10.1038/nature11159

Comments

Popular posts from this blog

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by...

Improved querying for SureChEMBL

    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never ...

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding ...

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen...

In search of the perfect assay description

Credit: Science biotech, CC BY-SA 4.0 Assays des cribe the experimental set-up when testing the activity of drug-like compounds against biological targets; they provide useful context for researchers interested in drug-target relationships. Ver sion 33 of ChEMBL contains 1.6 million diverse assays spanning ADMET, physicochemical, binding, functional and toxicity experiments. A set of well-defined and structured assay descriptions would be valuable for the drug discovery community, particularly for text mining and NLP projects. These would also support ChEMBL's ongoing efforts towards an  in vitro  assay classification. This Blog post will consider the features of the 'perfect' assay description and provide a guide for depositors on the submission of high quality data. ChEMBL's assays are typically structured with the overall aim, target, and method .  The ideal assay description is succinct but contains all the necessary information for easy interpretation by database u...